制药提价与抑制仿制药方式 472条(本栏目收费,不能显示细节,电话13136136841)
boy scout contract clauses, 59,61, 137 137
Product hopping by Endo and, 78,79 79
brand- name drug companies 0
costs to society of unscrupulous monopoly extensions and patent abuse by, 23 23
efforts of to block generic competition, 9 9
loss of market share after generic drug entry, 7 7
use of clinical trial data of by generic competitors, 22 22
business method patents, 83 83
carve- out requests, 103,104 104
carve- outs defined, 103 103
for generic Abilify (antipsychotic,Otsuka), 110,12 12
for generic Crestor (AstraZeneca),108,10, 111,12 12
for generic Skelaxin (KingPharmaceuticals), 105,108 108
Celgene (pharmaceutical company), 83,84 84
Cipro (antibiotic, Bayer) In re Cipro antitrust case, 46,47 47
NASDAQ’s Biotechnology Index, 1 1
new chemical entity (NCE) exclusivity, 32 32
Nexium (esomeprazole), 4 4
monopoly profits from, 9 9
product hopping of from Prilosec, 71,74 74
Niacor- SR (cholesterol drug, Upsher- Smith), 50 50
subversion of FDA guidelines and, 67 67
Egypt, deal with Gilead, 5,6 6
Elements to Assure Safe Use (ETASU), 81,82 82
Endo Pharmaceuticals, 94,95 95
product hopping via boy scout contract clause by, 78,79 79